Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study.

Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM.

World J Urol. 2019 Feb 13. doi: 10.1007/s00345-019-02678-x. [Epub ahead of print]

PMID:
30759271
2.

Is Malignant Germ-Cell Tumor Associated With Cowden Syndrome?

Rushin L, Reys B, Freifeld Y, Karpowicz M, Fetzer D, Bagrodia A.

Clin Genitourin Cancer. 2019 Jan 10. pii: S1558-7673(19)30010-2. doi: 10.1016/j.clgc.2019.01.002. [Epub ahead of print] No abstract available.

PMID:
30733184
3.

Considerations When Treating Patients with Good-risk Germ Cell Tumors.

Bagrodia A, Albany C, Cary C.

Eur Urol Focus. 2019 Jan 10. pii: S2405-4569(19)30002-1. doi: 10.1016/j.euf.2019.01.002. [Epub ahead of print]

PMID:
30639250
4.

Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (18F-Fluciclovine) PET/CT in a Patient With Recurrent Prostate Cancer.

Bhanvadia RR, Woldu SL, Margulis V, Subramaniam RM, Bagrodia A.

Clin Genitourin Cancer. 2019 Feb;17(1):e184-e186. doi: 10.1016/j.clgc.2018.10.014. Epub 2018 Oct 29. No abstract available.

PMID:
30454969
5.

Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.

Freifeld Y, Xi Y, Passoni N, Woldu S, Hornberger B, Goldberg K, Bagrodia A, Raj G, Margulis V, Cadeddu JA, Lotan Y, Francis F, Pedrosa I, G Roehrborn C, Costa DN.

Urol Oncol. 2019 Jan;37(1):57-62. doi: 10.1016/j.urolonc.2018.10.009. Epub 2018 Nov 13.

PMID:
30446460
6.

Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.

Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB.

Clin Cancer Res. 2019 Feb 1;25(3):967-976. doi: 10.1158/1078-0432.CCR-18-2039. Epub 2018 Oct 23.

PMID:
30352907
7.

Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.

Pietzak EJ, Zabor EC, Bagrodia A, Armenia J, Hu W, Zehir A, Funt S, Audenet F, Barron D, Maamouri N, Li Q, Teo MY, Arcila ME, Berger MF, Schultz N, Dalbagni G, Herr HW, Bajorin DF, Rosenberg JE, Al-Ahmadie H, Bochner BH, Solit DB, Iyer G.

Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2.

PMID:
30290956
8.

Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study.

Woldu SL, Matulay JT, Clinton TN, Singla N, Freifeld Y, Sanli O, Krabbe LM, Hutchinson RC, Lotan Y, Hammers H, Hannan R, Brugarolas J, Bagrodia A, Margulis V.

Clin Genitourin Cancer. 2018 Dec;16(6):e1221-e1235. doi: 10.1016/j.clgc.2018.08.001. Epub 2018 Aug 25.

PMID:
30217763
9.

Germ Cell Tumors: Updates on Epidemiology, Biology, and Treatment Considerations.

Bagrodia A, Albany C, Masterson TA.

Adv Urol. 2018 Aug 19;2018:4821084. doi: 10.1155/2018/4821084. eCollection 2018. No abstract available.

10.

Editorial comment.

Bagrodia A, Albers P.

Curr Opin Urol. 2018 Sep;28(5):433-434. doi: 10.1097/MOU.0000000000000524. No abstract available.

PMID:
30044318
11.

Update on epidemiologic considerations and treatment trends in testicular cancer.

Woldu SL, Bagrodia A.

Curr Opin Urol. 2018 Sep;28(5):440-447. doi: 10.1097/MOU.0000000000000532.

PMID:
30004908
12.

Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.

Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V.

Urol Oncol. 2018 Jul;36(7):343.e1-343.e8. doi: 10.1016/j.urolonc.2018.04.004. Epub 2018 May 7.

PMID:
29748098
13.

The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus.

Hutchinson R, Rew C, Chen G, Woldu S, Krabbe LM, Meissner M, Sheth K, Singla N, Shakir N, Master VA, Karam JA, Matin SF, Borregales LD, Wood C, Masterson T, Thompson RH, Boorjian SA, Leibovich BC, Abel EJ, Bagrodia A, Margulis V.

Urology. 2018 May;115:119-124. doi: 10.1016/j.urology.2018.02.019. Epub 2018 Feb 27.

PMID:
29499258
14.

Metastatic "Burned Out" Seminoma Causing Neurological Paraneoplastic Syndrome-Not Quite "Burned Out".

Freifeld Y, Kapur P, Chitkara R, Lee F, Khemani P, Bagrodia A.

Front Neurol. 2018 Jan 30;9:20. doi: 10.3389/fneur.2018.00020. eCollection 2018.

15.

A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.

Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, Lewin J, Atenafu EG, Sweet J, Anson-Cartwright L, Boström P, Chung P, Warde P, Bedard PL, Bagrodia A, Freifeld Y, Power N, Winquist E, Hamilton RJ.

Eur Urol Focus. 2018 Dec;4(6):995-1001. doi: 10.1016/j.euf.2018.01.015. Epub 2018 Feb 7.

PMID:
29428550
16.

Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma.

Margolin EJ, Matulay JT, Li G, Meng X, Chao B, Vijay V, Silver H, Clinton TN, Krabbe LM, Woldu SL, Singla N, Bagrodia A, Margulis V, Huang WC, Bjurlin MA, Shah O, Anderson CB.

J Urol. 2018 Jun;199(6):1440-1445. doi: 10.1016/j.juro.2018.02.002. Epub 2018 Feb 7.

PMID:
29427584
17.

Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens.

Bagrodia A, Audenet F, Pietzak EJ, Kim K, Murray KS, Cha EK, Sfakianos JP, Iyer G, Singla N, Arcila M, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA.

Eur Urol Focus. 2018 Jan 30. pii: S2405-4569(18)30006-3. doi: 10.1016/j.euf.2018.01.005. [Epub ahead of print]

PMID:
29396293
18.

Timing of blood transfusion and oncologic outcomes in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma.

Bagrodia A, Kaffenberger S, Winer A, Murray K, Vacchio M, Zheng J, Ostrovnaya I, Bochner BH, Dalbagni G, Cha EK, Coleman JA.

World J Urol. 2018 Apr;36(4):645-653. doi: 10.1007/s00345-018-2180-3. Epub 2018 Jan 17.

PMID:
29344681
19.

Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis.

Woldu SL, Ci B, Hutchinson RC, Krabbe LM, Singla N, Passoni NM, Clinton TN, Raj GV, Miller DS, Sagalowsky AI, Lotan Y, Xie Y, Margulis V, Bagrodia A.

Urol Oncol. 2018 Apr;36(4):159.e7-159.e17. doi: 10.1016/j.urolonc.2017.12.001. Epub 2017 Dec 26.

PMID:
29288008
20.

Tissue-based biomarkers in prostate cancer.

Clinton TN, Bagrodia A, Lotan Y, Margulis V, Raj GV, Woldu SL.

Expert Rev Precis Med Drug Dev. 2017;2(5):249-260. doi: 10.1080/23808993.2017.1372687. Epub 2017 Sep 5.

21.

Reply.

Woldu SL, Bagrodia A, Moore JA, Arriaga Y.

Urology. 2018 Feb;112:111. doi: 10.1016/j.urology.2017.08.061. Epub 2017 Dec 6. No abstract available.

PMID:
29198421
22.

Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses.

Woldu SL, Aydin AM, Rao AV, Hutchinson RC, Singla N, Clinton TN, Krabbe LM, Passoni NM, Raj GV, Miller DS, Amatruda JF, Sagalowsky AI, Lotan Y, Arriaga Y, Margulis V, Bagrodia A.

Urology. 2018 Feb;112:103-111. doi: 10.1016/j.urology.2017.08.059. Epub 2017 Dec 6.

PMID:
29079210
23.

Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-70.

Bagrodia A, Woldu S, Penson DF, Kutikov A, Kaffenberger SD.

Eur Urol. 2018 Apr;73(4):e98-e99. doi: 10.1016/j.eururo.2017.09.019. Epub 2017 Oct 9. No abstract available.

PMID:
29032846
24.

Impact of hospital case volume on testicular cancer outcomes and practice patterns.

Woldu SL, Matulay JT, Clinton TN, Singla N, Krabbe LM, Hutchinson RC, Sagalowsky A, Lotan Y, Margulis V, Bagrodia A.

Urol Oncol. 2018 Jan;36(1):14.e7-14.e15. doi: 10.1016/j.urolonc.2017.08.024. Epub 2017 Sep 19.

PMID:
28935185
25.

Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer.

Bagrodia A, Sukhu R, Winer AG, Levy E, Vacchio M, Lee B, Pietzak EJ, Donahue TF, Cha E, Iyer G, Sjoberg DD, Vickers AJ, Rosenberg JE, Bajorin DF, Dalbagni G, Bochner BH.

Clin Genitourin Cancer. 2017 Aug 10. pii: S1558-7673(17)30232-X. doi: 10.1016/j.clgc.2017.07.022. [Epub ahead of print]

26.

Prospects and progress of immunotherapy for bladder cancer.

Boegemann M, Aydin AM, Bagrodia A, Krabbe LM.

Expert Opin Biol Ther. 2017 Nov;17(11):1417-1431. doi: 10.1080/14712598.2017.1366445. Epub 2017 Aug 23. Review.

PMID:
28832261
27.

Re: Multi-institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy.

Bagrodia A, Lotan Y.

Eur Urol. 2017 Nov;72(5):857-858. doi: 10.1016/j.eururo.2017.06.017. Epub 2017 Jun 24. No abstract available.

PMID:
28655542
28.

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.

Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, Zehir A, Schultz N, Rosenberg JE, Bajorin DF, Dalbagni G, Al-Ahmadie H, Solit DB, Bochner BH.

Eur Urol. 2017 Dec;72(6):952-959. doi: 10.1016/j.eururo.2017.05.032. Epub 2017 Jun 3.

29.

Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.

Tumati V, Jackson WC, Abugharib AE, Raj G, Roehrborn C, Lotan Y, Courtney K, Bagrodia A, Gahan JC, Zumsteg ZS, Folkert MR, Laine AM, Hannan R, Spratt DE, Desai NB.

BJU Int. 2018 Mar;121(3):365-372. doi: 10.1111/bju.13926. Epub 2017 Jul 5.

PMID:
28581200
30.

Statin utilization improves oncologic and survival outcomes in patients with dyslipidemia and surgically treated renal cell carcinoma.

Berquist SW, Lee HJ, Hamilton Z, Bagrodia A, Hassan AE, Beksaç AT, Dufour CA, Wang S, Mehrazin R, Patterson A, Derweesh IH.

Minerva Urol Nefrol. 2017 Oct;69(5):501-508. doi: 10.23736/S0393-2249.17.02788-6. Epub 2017 Mar 30.

31.

Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence.

Li Q, Assel M, Benfante N, Pietzak E, Bagrodia A, Cha E, Dalbagni G, Coleman J.

J Urol. 2017 Sep;198(3):546-551. doi: 10.1016/j.juro.2017.03.120. Epub 2017 Mar 22.

32.

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.

Aydin AM, Woldu SL, Hutchinson RC, Boegemann M, Bagrodia A, Lotan Y, Margulis V, Krabbe LM.

Onco Targets Ther. 2017 Mar 9;10:1487-1502. doi: 10.2147/OTT.S109453. eCollection 2017. Review.

33.

Guideline of guidelines: non-muscle-invasive bladder cancer.

Woldu SL, Bagrodia A, Lotan Y.

BJU Int. 2017 Mar;119(3):371-380. doi: 10.1111/bju.13760. Epub 2017 Jan 24. Review.

34.

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.

Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR.

J Clin Oncol. 2016 Nov 20;34(33):4000-4007. doi: 10.1200/JCO.2016.68.7798. Epub 2016 Sep 30.

35.

Testicular germ cell tumor genomics.

Woldu SL, Amatruda JF, Bagrodia A.

Curr Opin Urol. 2017 Jan;27(1):41-47. Review.

36.

Genomic characterization of response to chemoradiation in urothelial bladder cancer.

Desai NB, Scott SN, Zabor EC, Cha EK, Hreiki J, Sfakianos JP, Ramirez R, Bagrodia A, Rosenberg JE, Bajorin DF, Berger MF, Bochner BH, Zelefsky MJ, Kollmeier MA, Ostrovnaya I, Al-Ahmadie HA, Solit DB, Iyer G.

Cancer. 2016 Dec 1;122(23):3715-3723. doi: 10.1002/cncr.30219. Epub 2016 Aug 1.

37.

Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15 year experience and lessons learned.

Gayed BA, Youssef R, Darwish O, Kapur P, Bagrodia A, Brugarolas J, Raj G, DiMaio JM, Sagalowsky A, Margulis V.

BMC Urol. 2016 Jul 19;16(1):43. doi: 10.1186/s12894-016-0157-3.

38.

Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study.

Passoni NM, Shariat SF, Bagrodia A, Francis F, Rachakonda V, Xylinas E, Kapur P, Sagalowsky AI, Lotan Y.

Bladder Cancer. 2016 Jan 7;2(1):91-99.

39.

Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.

Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, Jordan EJ, Gao SP, Ramirez R, Cha EK, Desai NB, Zabor EC, Ostrovnaya I, Gopalan A, Chen YB, Fine SW, Tickoo SK, Gandhi A, Hreiki J, Viale A, Arcila ME, Dalbagni G, Rosenberg JE, Bochner BH, Bajorin DF, Berger MF, Reuter VE, Taylor BS, Solit DB.

Nat Genet. 2016 Apr;48(4):356-8. doi: 10.1038/ng.3503. Epub 2016 Feb 22.

40.

Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.

Bagrodia A, Cha EK, Sfakianos JP, Zabor EC, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA, Iyer G, Scott SN, Shah R, Ostrovnaya I, Lee B, Desai NB, Ren Q, Rosenberg JE, Dalbagni G, Bajorin DF, Reuter VE, Berger MF; Collaborators.

J Urol. 2016 Jun;195(6):1684-1689. doi: 10.1016/j.juro.2016.01.006. Epub 2016 Jan 14.

41.

Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma.

Li Q, Bagrodia A, Cha EK, Coleman JA.

Curr Urol Rep. 2016 Feb;17(2):12. doi: 10.1007/s11934-015-0566-y. Review.

42.

Genomic Characterization of Upper Tract Urothelial Carcinoma.

Sfakianos JP, Cha EK, Iyer G, Scott SN, Zabor EC, Shah RH, Ren Q, Bagrodia A, Kim PH, Hakimi AA, Ostrovnaya I, Ramirez R, Hanrahan AJ, Desai NB, Sun A, Pinciroli P, Rosenberg JE, Dalbagni G, Schultz N, Bajorin DF, Reuter VE, Berger MF, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA.

Eur Urol. 2015 Dec;68(6):970-7. doi: 10.1016/j.eururo.2015.07.039. Epub 2015 Aug 14.

43.

Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?

Krabbe LM, Bagrodia A, Westerman ME, Gayed BA, Haddad AQ, Sagalowsky AI, Shariat SF, Kapur P, Lotan Y, Margulis V.

World J Urol. 2016 Jan;34(1):105-12. doi: 10.1007/s00345-015-1584-6. Epub 2015 May 20.

PMID:
25991599
44.

Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma.

Singla N, Gayed BA, Bagrodia A, Krabbe LM, Palazzi KL, Mirheydar H, Harrow B, Jacobs C, Youssef R, Darwish O, Sagalowsky A, Lotan Y, Derweesh I, Margulis V.

Urol Oncol. 2015 Jun;33(6):268.e1-7. doi: 10.1016/j.urolonc.2015.03.006. Epub 2015 Apr 7.

PMID:
25862284
45.

Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: preliminary results.

Gayed BA, Bagrodia A, Gaitonde M, Krabbe LM, Meissner M, Kapur P, Youssef RF, Sagalowsky A, Lotan Y, Margulis V.

Urol Oncol. 2015 Jan;33(1):18.e21-18.e26. doi: 10.1016/j.urolonc.2014.09.017. Epub 2014 Nov 7.

PMID:
25454486
46.

Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract.

Krabbe LM, Bagrodia A, Haddad AQ, Kapur P, Khalil D, Hynan LS, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V.

J Urol. 2015 May;193(5):1486-93. doi: 10.1016/j.juro.2014.11.007. Epub 2014 Nov 11.

PMID:
25451830
47.

Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.

Bagrodia A, Krabbe LM, Gayed BA, Kapur P, Bernstein I, Xie XJ, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclerq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V.

Urology. 2014 Nov;84(5):1134-40. doi: 10.1016/j.urology.2014.07.050. Epub 2014 Oct 24.

PMID:
25443916
48.

Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract.

Chung PH, Krabbe LM, Darwish OM, Westerman ME, Bagrodia A, Gayed BA, Haddad AQ, Kapur P, Sagalowsky AI, Lotan Y, Margulis V.

Urol Oncol. 2014 Oct;32(7):981-8. doi: 10.1016/j.urolonc.2014.02.018. Epub 2014 Jul 9.

PMID:
25022858
49.

Diagnosis and management of upper tract urothelial carcinoma.

Krabbe LM, Bagrodia A, Westerman ME, Margulis V.

Minerva Urol Nefrol. 2014 Mar;66(1):37-48. Review.

PMID:
24721939
50.

Impact of renal surgery for cortical neoplasms on lipid metabolism.

Bagrodia A, Kopp RP, Mehrazin R, Lee HJ, Liss MA, Jabaji R, Kane CJ, Wake RW, Patterson AL, Wan JY, Derweesh IH.

BJU Int. 2014 Dec;114(6):837-43. doi: 10.1111/bju.12744. Epub 2014 Jul 15.

Supplemental Content

Loading ...
Support Center